Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


J Am Soc Nephrol 17: 78-80, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2005121338
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitt, C. P.
Right arrow Articles by Ritz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitt, C. P.
Right arrow Articles by Ritz, E.

Proceedings of the Fourth Genoa Meeting on Hypertension, Diabetes, and Renal Diseases

Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality

Claus Peter Schmitt*, Tobias Odenwald* and Eberhard Ritz{dagger}

Departments of * Pediatrics and {dagger} Internal Medicine, Ruperto Carola University, Heidelberg, Germany

Address correspondence to: Prof. Dr. Eberhard Ritz, Nierenzentrum, Bergheimer Strasse 56a, D-69115 Heidelberg, Germany. Phone: +49-0-6221-91120; Fax: +49-0-6221-601705; E-mail: Prof.E.Ritz{at}t-online.de

Calcemia is a risk factor for cardiovascular (CV) events in dialyzed patients. The relation between serum calcium and cardiovascular events is continuous and linear. Calcium plays a potent role in the genesis of cardiovascular dysfunction, particularly by promoting vascular calcification. Parathyroid hormone (PTH) also is associated with increased CV risk in both primary and secondary hyperparathyroidism. There is a nonlinear relationship between PTH and CV risk; both high and low PTH concentrations increase CV risk. The CV risk profile (BP, dyslipidemia) is strikingly ameliorated by the administration of calcimimetics. Apart from lowering PTH, whether calcimimetics have intrinsic effects on CV risk profile is unknown.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
G. Rashid, J. Bernheim, J. Green, and S. Benchetrit
Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1023 - 1026.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673